Publications by authors named "A F Altenburg"
Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study.
J Eur Acad Dermatol Venereol
December 2024
Background: Adamantiades-Behçet's disease (ABD) is a rare, chronic, relapsing, multisystem vasculitis, with a reported prevalence of 0.9 out of 100,000 population in Germany in 2012. However, more recent epidemiological data are lacking.
View Article and Find Full Text PDFArticle Synopsis
- Major histocompatibility class I (MHC-I) molecules are crucial for presenting peptides on cell surfaces, helping the immune system detect infected or cancerous cells.
- TAPBPR, a molecule involved in the MHC-I antigen processing pathway, affects how peptides are loaded onto HLA-I by mediating their exchange, specifically through a flexible loop region.
- Research findings indicate that TAPBPR shapes the peptide repertoire for different HLA-I allotypes and performs its function in both peptide filtering and loading without needing the editing loop to keep HLA-I in an open state.
Adamantiades-Behçet disease is an inflammatory, vascular disease of unknown etiology. The disease is named after two physicians, Benediktos Adamantiades and Hulȗsi Behçet, who both made significant contributions to the study of the disease. It was probably first described by Hippocrates in 500 BCE.
View Article and Find Full Text PDFThe interaction between immune cells and virus-infected targets involves multiple plasma membrane (PM) proteins. A systematic study of PM protein modulation by vaccinia virus (VACV), the paradigm of host regulation, has the potential to reveal not only novel viral immune evasion mechanisms, but also novel factors critical in host immunity. Here, >1000 PM proteins were quantified throughout VACV infection, revealing selective downregulation of known T and NK cell ligands including HLA-C, downregulation of cytokine receptors including IFNAR2, IL-6ST and IL-10RB, and rapid inhibition of expression of certain protocadherins and ephrins, candidate activating immune ligands.
View Article and Find Full Text PDF